['type 1 diabetes mellitus']
['biochaperone insulin lispro', 'humalog®']

        Inclusion Criteria:

          -  Type 1 diabetes mellitus (as diagnosed clinically) ≥ 12 months

          -  Treated with multiple daily insulin injections (no pump users) ≥ 12 months

          -  Current total daily insulin treatment <1.2 (I)U/kg/day

          -  Body mass index (BMI) 18.5-28.0 kg/m² (both inclusive)

          -  HbA1c (N-(1-deoxy)-fructosyl-haemoglobin) ≤ 9.0% by local laboratory analysis

          -  Fasting C-peptide ≤ 0.30 nmol/L

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to trial products or related products

          -  Type 2 diabetes mellitus

          -  Patients using continuous subcutaneous insulin infusion (CSII)

          -  Previous participation in this trial. Participation is defined as randomised

          -  The receipt of any investigational product within 3 months prior to this trial

          -  Clinically significant abnormal haematology, biochemistry, lipids, or urinalysis
             screening tests, as judged by the Investigator considering the underlying disease

          -  Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea,
             vomiting, heartburn or diarrhoea), as judged by the Investigator

          -  Known slowing of gastric emptying and or gastrointestinal surgery that in the opinion
             of the investigator might change gastrointestinal motility and food absorption

          -  Unusual meal habits and special diet requirements or unwillingness to eat the food
             provided in the trial
      